Gracell Biotechnologies Inc reports results for the quarter ended in December - Earnings Summary

Gracell Biotechnologies

13/03/2023 13:30

* Gracell Biotechnologies Inc  GRCL.OQ  reported a quarterly
adjusted loss of 30 cents​​ per share for the quarter ended in
December. The mean expectation of seven analysts for the quarter
was for a loss of 13 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Gracell Biotechnologies Inc's reported EPS for the quarter
was a
loss of 30 cents​.
    * The mean earnings estimate of analysts had fallen by
about 6.1%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Gracell Biotechnologies Inc shares had fallen by 19.1%
this
quarter.
    * The company reported a quarterly loss of $18.95 million.
    * Wall Street's median 12-month price target for Gracell
Biotechnologies Inc is $12.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
March 13 at 01:30 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2022      -0.13          -0.30          Missed
 Sep. 30 2022      -0.13          -0.35          Missed
 Jun. 30 2022      -0.07          -0.30          Missed
 Mar. 31 2022      -0.21          -0.35          Missed